Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PMV Pharmaceuticals, Inc. (PMVP : NSDQ)
 
 • Company Description   
PMV Pharmaceuticals Inc.is a precision oncology company. It engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. PMV Pharmaceuticals Inc.is headquartered in Cranbury, New Jersey.

Number of Employees: 47

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.27 Daily Weekly Monthly
20 Day Moving Average: 212,545 shares
Shares Outstanding: 51.95 (millions)
Market Capitalization: $65.98 (millions)
Beta: 1.49
52 Week High: $1.82
52 Week Low: $0.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 16.51% 12.15%
12 Week 24.51% 4.73%
Year To Date -15.89% -21.24%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 Alexander Park Drive Suite 301
-
Princeton,NJ 08540
USA
ph: 609-642-6670
fax: -
investors@pmvpharma.com http://www.pmvpharma.com
 
 • General Corporate Information   
Officers
David H. Mack - President; Chief Executive Officer and Director
Richard Heyman - Director and Chairman of the Board
Michael Carulli - Chief Financial Officer
Arnold Levine - Director
Carol Gallagher - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 69353Y103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 51.95
Most Recent Split Date: (:1)
Beta: 1.49
Market Capitalization: $65.98 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.41
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -13.33%
vs. Previous Quarter: 24.44%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -32.54
12/31/24 - -29.32
ROA
06/30/25 - -
03/31/25 - -29.59
12/31/24 - -26.41
Current Ratio
06/30/25 - -
03/31/25 - 16.75
12/31/24 - 12.22
Quick Ratio
06/30/25 - -
03/31/25 - 16.75
12/31/24 - 12.22
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 3.08
12/31/24 - 3.40
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©